Western Drug Recalls Lidocaine Injection Due to Sterility Concerns
Western Drug is recalling Lidocaine Injection 1% and 2% due to a lack of assurance of sterility. The product was distributed nationwide in eight states.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a lack of assurance of sterility in an injectable drug, which poses a significant risk of serious injury or death if contaminated.
Plain-English summary
Western Drug Inc. is recalling Lidocaine Injection 1% and 2% (Rx) because of a lack of assurance of sterility. The recall involves 4 containers of the product.
The affected product was distributed nationwide in the United States, specifically in Arizona, California, Georgia, New Mexico, South Carolina, South Dakota, Texas, and Utah. All lots are included in this recall.
Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider or pharmacist for further instructions. The FDA has classified this recall as Class II.
The recalled product
- Product
- Lidocaine Injection 1% , 2%, Rx, Western Drug Inc. 106 E. Main Street, Springerville, Arizona 85938
- Manufacturer
- Western Drug
- Category
- Drug — Injectable
- Affected units
- 4
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- all lots
Distribution
Part of a larger recall action
This product is one of 91 recalled by Western Drug under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 91 products in this recall →Related recalls
Same manufacturer · Western Drug
See all →- SevereWestern Drug Recalls Sodium Hydroxide 10% Injection Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
- SevereWestern Drug Recalls Methylcobalamin Injection Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
- SevereWestern Drug Recalls Benadryl Injection Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
- SevereWestern Drug Recalls PZI 40 Insulin Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
- SevereWestern Drug Recalls Ketorolac Injection Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
Same hazard · sterility
See all →- SevereAurolab Trust Recalls FOCUS PI Eye Drops Due to Sterility Concerns
FDA (Drugs) · 2026-10-07
- SevereSterling Recalls Carboxymethylcellulose Sodium Eye Drops Due to Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereSterling Pharmaceutical Recalls Lubricating Tears Due to Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereWalgreens Lubricant Eye Drops Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2026-09-30
- SevereSodium Chloride Ophthalmic Solution Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
Similar recalls
- SevereLidocaine Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2019-04-24
- SevereGreen Valley Drugs Recalls Lidocaine Injections Due to Sterility Concerns
FDA (Drugs) · 2013-05-22
- SevereRXQ Compounding Recalls Lidocaine Injection Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- SeverePharmakon Recalls Lidocaine Syringes Due to Sterility Assurance Concerns
FDA (Drugs) · 2016-07-20
- HighLidocaine Injectable Solution Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2023-05-31
- SevereNorthwest Compounding Pharmacy Recalls Lidocaine Gel Due to Sterility Concerns
FDA (Drugs) · 2019-01-09